Arrowhead Pharmaceuticals Stock Analysis
ARWR Stock | USD 28.60 0.10 0.35% |
Arrowhead Pharmaceuticals is overvalued with Real Value of 24.02 and Target Price of 55.57. The main objective of Arrowhead Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Arrowhead Pharmaceuticals is worth, separate from its market price. There are two main types of Arrowhead Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Arrowhead Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Arrowhead Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Arrowhead Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Arrowhead Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Arrowhead Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Arrowhead Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Arrowhead |
Arrowhead Stock Analysis Notes
About 65.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings (P/E) ratio of 482.39. Arrowhead Pharmaceuticals recorded a loss per share of 2.77. The entity last dividend was issued on the 29th of October 2010. The firm had 1:10 split on the 17th of November 2011. Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Arrowhead Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 329 people. For more info on Arrowhead Pharmaceuticals please contact Christopher Anzalone at 626 304 3400 or go to https://arrowheadpharma.com.Arrowhead Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Arrowhead Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Arrowhead Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Arrowhead Pharmaceuticals generated a negative expected return over the last 90 days | |
Arrowhead Pharmaceuticals has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 240.74 M. Net Loss for the year was (209.28 M) with profit before overhead, payroll, taxes, and interest of 240.74 M. | |
Arrowhead Pharmaceuticals currently holds about 416.5 M in cash with (153.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.93. | |
Roughly 65.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from news.google.com: ARROWHEAD PHARMACEUTICALS INC. Trade Ideas SWBHDP1 TradingView - TradingView |
Arrowhead Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Arrowhead Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arrowhead Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of February 2024 Upcoming Quarterly Report | View | |
7th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
4th of December 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
30th of September 2023 Last Financial Announcement | View |
Arrowhead Largest EPS Surprises
Earnings surprises can significantly impact Arrowhead Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2020-02-05 | 2019-12-31 | -0.01 | -0.03 | -0.02 | 200 | ||
2018-02-09 | 2017-12-31 | -0.16 | -0.18 | -0.02 | 12 | ||
2017-02-06 | 2016-12-31 | -0.2 | -0.17 | 0.03 | 15 |
Arrowhead Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arrowhead Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arrowhead Pharmaceuticals backward and forwards among themselves. Arrowhead Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Arrowhead Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Capital Research & Mgmt Co - Division 3 | 2023-12-31 | 1.3 M | Northern Trust Corp | 2023-12-31 | 1.2 M | Rokos Capital Management Llp | 2023-12-31 | 1.2 M | Venbio Select Advisor Llc | 2023-12-31 | 1.1 M | Artal Group S A | 2023-12-31 | 1 M | Bank Of New York Mellon Corp | 2023-12-31 | 957.9 K | Ubs Asset Mgmt Americas Inc | 2023-12-31 | 951.3 K | Ameriprise Financial Inc | 2023-12-31 | 928.6 K | Woodline Partners Lp | 2023-12-31 | 927.2 K | Blackrock Inc | 2023-12-31 | 13.3 M | Vanguard Group Inc | 2023-12-31 | 10.7 M |
Arrowhead Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.54 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arrowhead Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Arrowhead Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Arrowhead Profitablity
Arrowhead Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Arrowhead Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Arrowhead Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Arrowhead Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Arrowhead Pharmaceuticals' profitability requires more research than a typical breakdown of Arrowhead Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (1.63) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (38.45) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $38.45. Last Reported | Projected for 2024 | ||
Return On Capital Employed | (0.31) | (0.32) | |
Return On Assets | (0.24) | (0.25) | |
Return On Equity | (0.87) | (0.91) |
Management Efficiency
Arrowhead Pharmaceuticals has return on total asset (ROA) of (0.2466) % which means that it has lost $0.2466 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0624) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/29/2024, Return On Capital Employed is likely to drop to -0.32. In addition to that, Return On Assets is likely to drop to -0.25. At this time, Arrowhead Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 03/29/2024, Non Current Assets Total is likely to grow to about 790.5 M, while Other Assets are likely to drop slightly above 229.4 K.Last Reported | Projected for 2024 | ||
Price Book Value Ratio | 9.51 | 4.80 | |
Enterprise Value Multiple | (17.56) | (18.43) | |
Price Fair Value | 9.51 | 4.80 |
The analysis of Arrowhead Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Arrowhead Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Arrowhead Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.721 |
Technical Drivers
As of the 29th of March, Arrowhead Pharmaceuticals shows the Risk Adjusted Performance of 0.0079, mean deviation of 3.06, and Standard Deviation of 4.15. Arrowhead Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and break down thirteen technical drivers for Arrowhead Pharmaceuticals, which can be compared to its rivals. Please confirm Arrowhead Pharmaceuticals information ratio and kurtosis to decide if Arrowhead Pharmaceuticals is priced correctly, providing market reflects its regular price of 28.6 per share. Given that Arrowhead Pharmaceuticals has information ratio of (0.03), we suggest you to validate Arrowhead Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Arrowhead Pharmaceuticals Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Arrowhead Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Arrowhead Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Arrowhead Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arrowhead Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arrowhead Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arrowhead Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lu Hongbo over a week ago Acquisition by Lu Hongbo of 1000 shares of Arrowhead Pharmaceuticals at 28.0 subject to Rule 16b-3 | ||
Kenneth Myszkowski over two weeks ago Disposition of 15000 shares by Kenneth Myszkowski of Arrowhead Pharmaceuticals at 36.2 subject to Rule 16b-3 | ||
Vakiener Victoria over two months ago Sale by Vakiener Victoria of 3620 shares of Arrowhead Pharmaceuticals | ||
Olukotun Adeoye Y over three months ago Acquisition by Olukotun Adeoye Y of 14987 shares of Arrowhead Pharmaceuticals subject to Rule 16b-3 | ||
San Martin Javier over three months ago Sale by San Martin Javier of 14758 shares of Arrowhead Pharmaceuticals | ||
Vakiener Victoria over three months ago Sale by Vakiener Victoria of 1550 shares of Arrowhead Pharmaceuticals |
Arrowhead Pharmaceuticals Predictive Daily Indicators
Arrowhead Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Arrowhead Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 21065.72 | |||
Daily Balance Of Power | (0.1) | |||
Rate Of Daily Change | 1.0 | |||
Day Median Price | 28.56 | |||
Day Typical Price | 28.57 | |||
Price Action Indicator | (0.01) | |||
Period Momentum Indicator | (0.10) |
Arrowhead Pharmaceuticals Corporate Filings
F4 | 20th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 19th of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 18th of March 2024 An amendment to a previously filed Form 8-K | ViewVerify |
F4 | 8th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
28th of February 2024 Other Reports | ViewVerify | |
27th of February 2024 Other Reports | ViewVerify | |
8K | 22nd of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 13th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
Arrowhead Pharmaceuticals Forecast Models
Arrowhead Pharmaceuticals' time-series forecasting models are one of many Arrowhead Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Arrowhead Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Arrowhead Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Arrowhead Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Arrowhead shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Arrowhead Pharmaceuticals. By using and applying Arrowhead Stock analysis, traders can create a robust methodology for identifying Arrowhead entry and exit points for their positions.
Last Reported | Projected for 2024 | ||
Pretax Profit Margin | (0.99) | (1.04) | |
Operating Profit Margin | (0.98) | (1.03) | |
Net Loss | (0.98) | (1.03) | |
Gross Profit Margin | 0.85 | 0.57 |
Current Arrowhead Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Arrowhead analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Arrowhead analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
55.57 | Strong Buy | 14 | Odds |
Most Arrowhead analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Arrowhead stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Arrowhead Pharmaceuticals, talking to its executives and customers, or listening to Arrowhead conference calls.
Arrowhead Stock Analysis Indicators
Arrowhead Pharmaceuticals stock analysis indicators help investors evaluate how Arrowhead Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Arrowhead Pharmaceuticals shares will generate the highest return on investment. By understating and applying Arrowhead Pharmaceuticals stock analysis, traders can identify Arrowhead Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 108 M | |
Common Stock Shares Outstanding | 106.8 M | |
Total Stockholder Equity | 271.3 M | |
Total Cashflows From Investing Activities | -96.2 M | |
Tax Provision | 2.8 M | |
Quarterly Earnings Growth Y O Y | 0.098 | |
Property Plant And Equipment Net | 335.6 M | |
Cash And Short Term Investments | 110.9 M | |
Cash | 110.9 M | |
Accounts Payable | 35.9 M | |
Net Debt | 4.3 M | |
50 Day M A | 31.1644 | |
Total Current Liabilities | 866 K | |
Other Operating Expenses | 445.7 M | |
Non Current Assets Total | 654.7 M | |
Forward Price Earnings | 111.1111 | |
Non Currrent Assets Other | 361.9 M | |
Stock Based Compensation | 78.1 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Arrowhead Stock analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Arrowhead Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.098 | Earnings Share (2.77) | Revenue Per Share 1.697 | Quarterly Revenue Growth (0.94) | Return On Assets (0.25) |
The market value of Arrowhead Pharmaceuticals is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arrowhead Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrowhead Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.